{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:23:40Z","timestamp":1791015820900,"version":"4.1.0"},"reference-count":132,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T00:00:00Z","timestamp":1536796800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00404","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T06:47:28Z","timestamp":1536821248000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Emerging Therapies in the Management of Advanced-Stage Gastric Cancer"],"prefix":"10.3389","volume":"9","author":[{"given":"Vivek","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parita","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kamholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav B.","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1158\/0008-5472.CAN-07-6334","article-title":"Is tumor growth sustained by rare cancer stem cells or dominant clones?","volume":"68","author":"Adams","year":"2008","journal-title":"Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1749-6632.2009.04911.x","article-title":"Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?","volume":"1171","author":"Aggarwal","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.6004\/jnccn.2016.0137","article-title":"Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Ajani","year":"2016","journal-title":"J. Natl. Comprehen. Cancer Netw."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","article-title":"Japanese gastric cancer treatment guidelines 2014 (ver. 4)","volume":"20","author":"Association","year":"2017","journal-title":"Gastric Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/annonc\/mdx002","article-title":"First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors","volume":"28","author":"Bang","year":"","journal-title":"Ann Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.2014.60.0320","article-title":"Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer","volume":"33","author":"Bang","year":"2015","journal-title":"J. Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1200\/JCO.2017.35.15_suppl.4012","article-title":"KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer","volume":"35","author":"Bang","year":"","journal-title":"American Society of Clinical Oncology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40425-017-0288-4","article-title":"32nd annual meeting and pre-conference programs of the society for immunotherapy of cancer (SITC 2017): part two","volume":"5","author":"Bang","year":"","journal-title":"J Immunothe Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","author":"Bang","year":"2017","journal-title":"J. Clin. Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1200\/jco.2015.33.15_suppl.4069","article-title":"Phase Ib\/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma","volume":"33","author":"Becerra","year":"2015","journal-title":"J Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/cncr.30538","article-title":"Identifying and targeting cancer stem cells in the treatment of gastric cancer","volume":"123","author":"Bekaii-Saab","year":"2017","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"TPS217","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4139","article-title":"A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma","volume":"35","author":"Bendell","year":"","journal-title":"American Society of Clinical Oncology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1200\/JCO.2016.34.15_suppl.4033","article-title":"Results of a phase I study of GS-5745 in combination with mFOLFOX in patients with advanced unresectable gastric\/GE junction tumors","volume":"34","author":"Bendell","year":"","journal-title":"J. Clin. Oncol."},{"key":"B15","volume-title":"Aduro Biotech Provides Update on CRS-207 Programs.","author":"Biotech","year":"2018"},{"key":"B16","doi-asserted-by":"publisher","first-page":"24269","DOI":"10.18632\/oncotarget.8169","article-title":"PD-L1 is an independent prognostic predictor in gastric cancer of Western patients","volume":"7","author":"B\u00f6ger","year":"2016","journal-title":"Oncotarget"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti-pd-l1 antibody avelumab (MSB0010718C) on human tumor cells","volume":"3","author":"Boyerinas","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"2012","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00535-015-1125-5","article-title":"Gastric cancer stem cells: evidence, potential markers, and clinical implications","volume":"51","author":"Brungs","year":"2016","journal-title":"J. Gastroenterol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"CT050","DOI":"10.1158\/1538-7445.AM2016-CT050","article-title":"Abstract CT050: a phase I\/II study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3, in patients with solid tumors","volume":"76","author":"Calvo","year":"2016","journal-title":"AACR"},{"key":"B21","doi-asserted-by":"publisher","first-page":"11411","DOI":"10.3748\/wjg.v21.i40.11411","article-title":"Tight junction disruption: helicobacter pylori and dysregulation of the gastric mucosal barrier","volume":"21","author":"Caron","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.critrevonc.2009.01.004","article-title":"Gastric cancer","volume":"71","author":"Catalano","year":"2009","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"mdx302","DOI":"10.1093\/annonc\/mdx302.008","article-title":"LBA-009KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric\/gastroesophageal (G\/GEJ) cancer","volume":"28","author":"Catenacci Daniel","year":"2017","journal-title":"Ann. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/JCO.2018.36.4_suppl.140","article-title":"Phase 1b\/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA)","volume":"6","author":"Catenacci","year":"2018","journal-title":"Am. Soc. Clin. Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3892\/ol.2014.2768","article-title":"Expression levels of matrix metalloproteinase-9 in human gastric carcinoma","volume":"9","author":"Chen","year":"2015","journal-title":"Oncol. Lett."},{"key":"B26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1200\/JCO.2016.34.15_suppl.4009","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: analysis of safety and clinical activity","volume":"34","author":"Chung","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B28","unstructured":"Claudiximab- AdisInsight [Online]2017"},{"key":"B29","unstructured":"A Study of IMU-131 Plus Standard of Care Chemotherapy in Patients With HER2\/Neu Overexpressing Advanced Cancer of the Stomach - Full Text View - ClinicalTrials.gov [Online]2018"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1200\/jco.2013.31.15_suppl.4011","article-title":"Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: a New York Cancer Consortium led phase II randomized study","volume":"31","author":"Cohen","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1200\/jco.2015.33.15_suppl.4000","article-title":"Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G\/GEJ) cancer: RILOMET-1 study","volume":"33","author":"Cunningham","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"djv439","DOI":"10.1093\/jnci\/djv439.","article-title":"Chimeric antigen receptors modified T-cells for cancer therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0124151","DOI":"10.1371\/journal.pone.0124151","article-title":"The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients","volume":"10","author":"Deng","year":"2015","journal-title":"PLoS ONE"},{"key":"B35","doi-asserted-by":"publisher","first-page":"32925","DOI":"10.18632\/oncotarget.9076","article-title":"Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers","volume":"7","author":"Derks","year":"2016","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1158\/2326-6066.CIR-15-0046","article-title":"Epithelial PD-L2 expression marks Barrett's esophagus and esophageal adenocarcinoma","volume":"3","author":"Derks","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B37","volume-title":"Definition of HER-2-Positive B-Cell Peptide Antigen IMU-131.","author":"Dictionary","year":""},{"key":"B38","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.4252\/wjsc.v7.i9.1185","article-title":"Therapies targeting cancer stem cells: current trends and future challenges","volume":"7","author":"Dragu","year":"2015","journal-title":"World J. Stem Cells"},{"key":"B39","doi-asserted-by":"publisher","first-page":"ii82","DOI":"10.1093\/annonc\/mdw199.272","article-title":"JAVELIN Gastric 300: Phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC \u00b1 chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer. (2017)","volume":"27","author":"Eric","year":"2017","journal-title":"Ann. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s10120-015-0519-7","article-title":"Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection","volume":"19","author":"Eto","year":"2016","journal-title":"Gastric Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/cancers6010240","article-title":"Gelatinase B\/MMP-9 in tumour pathogenesis and progression","volume":"6","author":"Farina","year":"2014","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1758834015616935","article-title":"Novel targets in the treatment of advanced gastric cancer: a perspective review","volume":"8","author":"Fontana","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial","volume":"15","author":"Ford","year":"2014","journal-title":"Lancet Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2017.35.15_suppl.4003","article-title":"KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer","volume":"35","author":"Fuchs","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamaoncol.2016.3015","article-title":"A quantitative comparison of antibodies to programmed cell death 1 ligand 1","volume":"3","author":"Gaule","year":"2017","journal-title":"JAMA Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s10120-016-0594-4","article-title":"Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy","volume":"20","author":"Giampieri","year":"2017","journal-title":"Gastric Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1158\/1538-7445.AM2016-3204","article-title":"INCAGN01949: an anti-OX40 agonist antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells","volume":"76","author":"Gonzalez","year":"2016","journal-title":"AACR"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1038\/cti.2016.27","article-title":"A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses","volume":"5","author":"Grenga","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"6659","DOI":"10.4049\/jimmunol.0804211","article-title":"Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells","volume":"182","author":"Grosso","year":"2009","journal-title":"J. Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.apsb.2013.02.006","article-title":"Cancer stem cells: therapeutic implications and perspectives in cancer therapy","volume":"3","author":"Han","year":"2013","journal-title":"Acta Pharm. Sin. B"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/cas.12986","article-title":"LAG-3, an important immune checkpoint in cancer","volume":"107","author":"He","year":"2016","journal-title":"Cancer Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/jco.2014.32.15_suppl.2530","article-title":"A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies","volume":"32","author":"Hitron","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"27359","DOI":"10.18632\/oncotarget.4751","article-title":"LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"key":"B56","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2018.36.4_suppl.118","article-title":"Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer","volume":"36","author":"Iwasa","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1073\/pnas.1118910109","article-title":"Mechanical compression drives cancer cells toward invasive phenotype","volume":"109","author":"Janet","year":"2012","journal-title":"Proc. Natl. Aca. Sci. U.S.A."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1200\/JCO.2017.35.15_suppl.4014","article-title":"Nivolumab\u00b1ipilimumab in pts with advanced (adv)\/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study","volume":"35","author":"Janjigian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"37762","DOI":"10.18632\/oncotarget.9326","article-title":"The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells","volume":"7","author":"Jochems","year":"2016","journal-title":"Oncotarget"},{"key":"B60","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/1758834015571111","article-title":"MEK and PI3K inhibition in solid tumors: rationale and evidence to date","volume":"7","author":"Jokinen","year":"2015","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"421821","DOI":"10.1155\/2013\/421821","article-title":"Role of STAT3 in cancer metastasis and translational advances","volume":"2013","author":"Kamran","year":"2013","journal-title":"BioMed Res. Int."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","article-title":"Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone","volume":"30","author":"Kang","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"","journal-title":"Lancet"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.4_suppl.2","article-title":"Nivolumab (ONO-4538\/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial","author":"Kang","year":"","journal-title":"Am. Soc. Clin. Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"300","DOI":"10.14694\/EDBK_175231","article-title":"Immunotherapy for Esophageal and Gastric Cancer American Society of Clinical Oncology educational book","volume":"292","author":"Kelly","year":"2017","journal-title":"Am. Soc. Clin. Oncolo. Meet."},{"key":"B66","doi-asserted-by":"publisher","first-page":"P157","DOI":"10.1186\/2051-1426-3-S2-P157","article-title":"Phase Ib\/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric\/gastroesophageal junction adenocarcinoma","volume":"3","author":"Kelly","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"TPS4131","DOI":"10.1200\/JCO.2017.35.4_suppl.TPS212","article-title":"CheckMate 577: a randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer","volume":"35","author":"Kelly","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.06.028","article-title":"Rationale for anti-GITR cancer immunotherapy","volume":"67","author":"Knee","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.4161\/cc.29212","article-title":"Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines","volume":"13","author":"Kubota","year":"2014","journal-title":"Cell Cycle"},{"key":"B70","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3390\/cancers4030873","article-title":"Therapeutic targeting of hyaluronan in the tumor stroma","volume":"4","author":"Kultti","year":"2012","journal-title":"Cancers"},{"key":"B71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1158\/0008-5472.CAN-13-2309","article-title":"CD44v8-10 is a cancer-specific marker for gastric cancer stem cells","volume":"74","author":"Lau","year":"2014","journal-title":"Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1073\/pnas.1424171112","article-title":"Suppression of cancer relapse and metastasis by inhibiting cancer stemness","volume":"112","author":"Li","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1136\/gutjnl-2014-308252","article-title":"Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas","volume":"64","author":"Lin","year":"2015","journal-title":"Gut"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e0127063","DOI":"10.1371\/journal.pone.0127063","article-title":"Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer","volume":"10","author":"Marshall","year":"2015","journal-title":"PLoS ONE"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/j.1349-7006.2007.00490.x","article-title":"Gastric and intestinal claudin expression at the invasive front of gastric carcinoma","volume":"98","author":"Matsuda","year":"2007","journal-title":"Cancer Sci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3390\/cancers6031441","article-title":"The role of PI3K\/Akt\/mTOR signaling in gastric carcinoma","volume":"6","author":"Matsuoka","year":"2014","journal-title":"Cancers"},{"key":"B79","doi-asserted-by":"publisher","first-page":"TPS195","DOI":"10.1200\/JCO.2018.36.4_suppl.TPS195","article-title":"JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC\/GEJC)","volume":"36","author":"Moehler","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"TPS4134","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS4134","article-title":"Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: The phase 3 JAVELIN Gastric 100 trial","volume":"34","author":"Moehler","year":"2016","journal-title":"Am. Soc. Clin. Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/path.1847","article-title":"Barrett's oesophagus is characterized by a predominantly humoral inflammatory response","volume":"207","author":"Moons","year":"2005","journal-title":"J. Pathol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","article-title":"Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu\u2013positive metastatic breast cancer","volume":"26","author":"Musolino","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B84","unstructured":"NCI Drug DictionaryDictionaryN. C. I. D. Definition of anti-AG7 antibody drug conjugate AbGn-107 - NCI Drug Dictionary - National Cancer Institute [Online]"},{"key":"B85","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/sj.cgt.7701080","article-title":"A phase 1 trial of CRS-207 in advanced solid tumor patients","volume":"14","author":"Nemunaitis","year":"2008","journal-title":"Cancer Gene Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"key":"B87","author":"Newswire","year":"2017","journal-title":"Ganymed to Present Exciting Phase II Clinical Data for IMAB362 in Gastroesophageal Cancer at ASCO 2016 Annual Meeting."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-15-2157","article-title":"Characterization of biomarkers of tumorigenic and chemoresistant cancer stem cells in human gastric carcinoma","volume":"3","author":"Nguyen","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1200\/jco.2016.34.4_suppl.168","article-title":"Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric or gastroesophageal junction cancer","volume":"34","author":"Nishina","year":"2016","journal-title":"Am. Soc. Clin. Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/bcr3069","article-title":"Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc\u03b3 receptor binding properties","volume":"13","author":"Nordstrom","year":"2011","journal-title":"Breast Cancer Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1200\/JCO.2012.48.3552","article-title":"Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study","volume":"31","author":"Ohtsu","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1002\/ijc.30408","article-title":"HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research","volume":"139","author":"Pietrantonio","year":"2016","journal-title":"Int. J. Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.3748\/wjg.v20.i16.4483","article-title":"Characteristics of gastric cancer in Asia","volume":"20","author":"Rahman","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/cncr.29363","article-title":"Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: a SWOG cooperative group trial (S1005)","volume":"121","author":"Ramanathan","year":"2015","journal-title":"Cancer"},{"key":"B95","unstructured":"RosenbergS. A. Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer - Full Text View - ClinicalTrials.gov [Online]2018"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e15079","DOI":"10.1200\/jco.2015.33.15_suppl.e15079","article-title":"IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): clinical activity and safety data from the PILOT phase I trial","volume":"33","author":"Sahin","year":"2015","journal-title":"Am. Soc. Clin. Oncol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN\u2013a randomized, phase III study","volume":"32","author":"Satoh","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e1100789","DOI":"10.1080\/2162402X.2015.1100789","article-title":"Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma","volume":"5","author":"Schl\u00f6\u00dfer","year":"2016","journal-title":"Oncoimmunology"},{"key":"B100","doi-asserted-by":"publisher","first-page":"614O","DOI":"10.1093\/annonc\/mdw371.06","article-title":"Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18. 2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18. 2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma","volume":"27","author":"Schuler","year":"2016","journal-title":"Ann. Oncol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1200\/JCO.2017.35.15","article-title":"Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction, and esophageal cancers: Results from the FAST study","volume":"35","author":"Schuler","year":"2017","journal-title":"Am. Soc. Clin. Oncol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/jco.2014.32.15_suppl.3002","article-title":"Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody","volume":"32","author":"Segal","year":"2014","journal-title":"Am. Soc. Clin. Oncol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/sj.bjc.6690180","article-title":"Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate","volume":"79","author":"Set\u00e4l\u00e4","year":"1999","journal-title":"Br. J. Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"TPS4141","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4141","article-title":"A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma","volume":"35","author":"Shah","year":"","journal-title":"J. Clin. Oncol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"TPS4139","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS4144","article-title":"The BRIGHTER trial: A phase III randomized double-blind study of BBI608+ weekly paclitaxel versus placebo (PBO)+ weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma","volume":"33","author":"Shah","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1200\/JCO.2017.35.4_suppl.108","article-title":"Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 and mFOLFOX6 in patients with advanced gastric\/gastroesophageal junction cancer","volume":"35","author":"Shah","year":"","journal-title":"J. Clin. Oncol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1200\/jco.2015.33.15_suppl.5513","article-title":"A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation","volume":"33","author":"Shapira-Frommer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e15089","DOI":"10.1200\/jco.2015.33.15_suppl.e15089","article-title":"A phase I study of BBI608, a cancer stemness inhibitor, administered with paclitaxel (PTX) as combination therapy (Rx) for pretreated unresectable or recurrent gastric cancer","volume":"33","author":"Shitara","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann. Oncol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/PPO.0b013e3181eb3343","article-title":"Indoleamine 2, 3-dioxygenase: is it an immune suppressor?","volume":"16","author":"Soliman","year":"2010","journal-title":"Cancer J."},{"key":"B111","doi-asserted-by":"publisher","first-page":"mdx369","DOI":"10.1093\/annonc\/mdx369","article-title":"616OPertuzumab (P)+ trastuzumab (H)+ chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC\/GEJC): Final analysis of a Phase III study (JACOB)","volume":"28","author":"Tabernero","year":"2017","journal-title":"Ann. Oncol"},{"key":"B112","first-page":"39","article-title":"Upregulation of immune checkpoint molecules, PD-1 and LAG-3, on CD4+ and CD8+ T cells after gastric cancer surgery","volume":"58","author":"Takaya","year":"2015","journal-title":"Yonago Acta Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/1535-7163.MCT-10-0470","article-title":"Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models","volume":"9","author":"Thompson","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/gutjnl-2015-310839","article-title":"Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma","volume":"66","author":"Thompson","year":"2016","journal-title":"Gut"},{"key":"B116","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/GICTT.S113525","article-title":"PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence","volume":"7","author":"Tran","year":"2017","journal-title":"Gastrointestinal Cancer"},{"key":"B118","doi-asserted-by":"publisher","first-page":"iv218","DOI":"10.1093\/annonc\/mdu334.21","article-title":"636P efficacy and safety of multiple doses of imab362 in patients with advanced gastro-esophageal cancer: results of a phase ii study","volume":"25","author":"Trarbach","year":"2014","journal-title":"Ann. Oncol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12929-017-0341-0","article-title":"Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets","volume":"24","author":"Tsai","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"B120","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1200\/JCO.2011.39.9824","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial","volume":"14","author":"Waddell","year":"2013","journal-title":"Lancet Oncol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","article-title":"Identification of T-cell receptors targeting KRAS-mutated human tumors","volume":"4","author":"Wang","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B123","first-page":"5059","article-title":"Role of cancer stem cell marker CD44 in gastric cancer: a meta-analysis","volume":"7","author":"Wang","year":"2014","journal-title":"Int. J. Clin. Exp. Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fimmu.2018.00384","article-title":"Novel Approaches to exploiting invariant NKT Cells in Cancer immunotherapy","volume":"9","author":"Wolf","year":"2018","journal-title":"Front. Immunol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"key":"B128","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.acthis.2006.01.003","article-title":"Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance","volume":"108","author":"Wu","year":"2006","journal-title":"Acta Histochem."},{"key":"B129","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.canlet.2016.02.032","article-title":"Helicobacter pylori upregulates Nanog and Oct4 via Wnt\/\u03b2-catenin signaling pathway to promote cancer stem cell-like properties in human gastric cancer","volume":"374","author":"Yong","year":"2016","journal-title":"Cancer Lett."},{"key":"B130","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13045-017-0522-z","article-title":"Recent advances of bispecific antibodies in solid tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"e1251539","DOI":"10.1080\/2162402X.2016.1251539","article-title":"CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside","volume":"5","author":"Zhang","year":"2016","journal-title":"Oncoimmunology"},{"key":"B132","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.7314\/APJCP.2012.13.6.2903","article-title":"Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis","volume":"13","author":"Zhang","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00404\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T02:44:24Z","timestamp":1693881864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00404\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,13]]},"references-count":132,"alternative-id":["10.3389\/fphar.2018.00404"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00404","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,13]]},"article-number":"404"}}